12:00 AM
 | 
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ruconest conestat alfa regulatory update

Pharming and partner Santarus Inc. (NASDAQ:SNTS, San Diego, Calif.) said Pharming submitted a BLA to FDA for Ruconest conestat alfa to treat acute attacks of hereditary angioedema (HAE). FDA refused to file a BLA for the product in 2011 (see...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >